CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Washington University School of Medicine
Seagen Inc.
Servier
Daiichi Sankyo
Merck Sharp & Dohme LLC
Neonc Technologies, Inc.
Shanghai Henlius Biotech
Seagen Inc.
Qurient Co., Ltd.
AstraZeneca
Seagen Inc.
Tizona Therapeutics, Inc
Essen Biotech
Genentech, Inc.
Nouscom SRL
H. Lee Moffitt Cancer Center and Research Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Takeda
RemeGen Co., Ltd.
Rutgers, The State University of New Jersey
ImmunityBio, Inc.
Amgen